Navigation Links
Discharge of First U.S. DuraHeart(TM) Patient
Date:8/21/2008

ANN ARBOR, Mich., Aug. 21 /PRNewswire/ Terumo Heart, Inc. today announced the discharge of the first U.S. patient implanted with the DuraHeart(TM) Left Ventricular Assist System (LVAS). The patient was discharged home on August 14th, from the University of Michigan Health System, 15 days after receiving the device.

The patient is a 62-year-old man from Livonia, Michigan, who has been suffering from heart failure for nearly 20 years. He is the first U.S. patient to receive a ventricular assist system that utilizes advanced magnetic levitation (Mag-Lev), a new, innovative type of technology.

Dr Pagani, National Co-Principal Investigator for the U.S. pivotal trial of the DuraHeart LVAS commented on the recent discharge. "We are extremely pleased with the performance of the DuraHeart and the recovery of our patient to an excellent functional state to permit discharge. We look forward to expanding upon our early experience with the DuraHeart in the near future."

The goal of these devices is to return the patient back to a relatively normal lifestyle and to provide improved "quality of life." "We are delighted that the FDA has allowed us to begin this trial with no restriction on patient discharge, which has not been true of some of the other devices currently conducting Trials in the United States," said Chisato Nojiri, M.D., PhD, Chief Executive Officer for Terumo Heart, Inc.

Earlier generation Left Ventricular Assist devices are prone to hemolysis, blood clots and mechanical failure. Significant advances have been made in the DuraHeart LVAS to potentially overcome these problems. Dr. Nojiri explained: "We have a unique pump design that combines advanced "Mag-Lev" technology and a centrifugal pump. The "Mag-Lev" allows for the complete elimination of mechanical contact within the blood flow path, minimizing the chance of mechanical failure. This is expected to significantly improve the clinical performance and long-term potential of this type of therapy." It has been used in more than 70 patients in Europe with the longest ongoing support over 3 years.

The DuraHeart Bridge-to-Transplant Pivotal Trial is a multi-center, prospective, non-randomized study of 140 patients and will include up to 40 centers. The device is intended to provide cardiac support for patients awaiting transplant who are at risk of death due to end-stage left ventricular failure. The National Co-Principal Investigators are Francis Pagani, M.D., Ph.D., from the University of Michigan and Yoshifumi Naka, M.D., Ph.D., from Columbia Presbyterian Hospital in New York.

Terumo Heart, Inc. is a US subsidiary of Terumo Corporation with headquarters and manufacturing facilities in Ann Arbor, Michigan. The company's focus is the innovation and introduction of products to improve the quality of healthcare for heart failure patients. Terumo Corporation, located in Tokyo, Japan, is a leading developer, manufacturer and global marketer of a wide array of medical products.

For more information, please contact Carmen Fox, Senior Marketing Communications Specialist, Terumo Heart, Inc. at (734) 741-6345 or carmen.fox@terumomedical.com.


'/>"/>
SOURCE Terumo Heart, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. First FLEXUS(TM) Interspinous Spacer Surgeries for IDE Clinical Trial
2. Cell Therapeutics Announces that the European Organization for Research and Treatment of Cancer Completes Enrollment in Phase II Clinical Trial of Brostallicin as First Line Therapy for Advanced or Metastatic Soft Tissue Sarcoma
3. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
4. Alexion Secures U.S. Patent for ALXN6000, a First-In-Class Anti-CD200 Monoclonal Antibody
5. First DuraHeart(TM) Left Ventricular Assist System Implanted in the U.S. Pivotal Trial
6. First U.S. Patient to Receive New Heart-Assist Device Doing Well After Surgery at University of Michigan
7. MicroDose Technologies Announces Achievement of Phase I Clinical Milestone Triggering First Milestone Payment Under Collaboration with Merck & Co., Inc.
8. First Molecular Tem-PCR Test to Identify Multiple Forms of Staph and MRSA Obtains CLIA Certificate
9. Sanofi Pasteur Shipping First Doses of Influenza Vaccine for the 2008-2009 Season in the US
10. First Ever Study on Alzheimers Disease Treatment in Hispanics Presented at Major Medical Meeting
11. Seattles Swedish Cancer Institute First in U.S. to Treat Cancer Patient with Elekta VMAT
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... 2017 According to a new market research ... R&D, Compliance, SCM), Component (Software, Service), Delivery (On premise, Cloud), End ... by MarketsandMarkets, the market is expected to reach USD 24.73 Billion ... of 13.3% during the forecast period. ... ...
(Date:1/21/2017)...  Faruqi & Faruqi, LLP, a leading national securities law ... (NASDAQ: KMPH ) of the federal securities class ... directors and underwriters of the Company,s April 16, 2015 Initial ... plaintiff. The lawsuit has been filed in the ... Johnson County on behalf of all those who ...
(Date:1/20/2017)... , January 20, 2017 Stock-Callers.com today ... SGYP ), Novo Nordisk A/S (NYSE: ... and Pernix Therapeutics Holdings Inc. (NASDAQ: PTX ). ... Thursday, January 19 th , 2017, finishing near its session ... Index dropped over 0.7%, while shares of health care companies ...
Breaking Medicine Technology:
(Date:1/23/2017)... ... January 23, 2017 , ... METTLER TOLEDO has announced ... by Applying Simple PAT Tools . , Crystallization is a common ... desired product. Chemists now spend more time developing better intermediate and final ...
(Date:1/23/2017)... ... January 23, 2017 , ... Steviva ... organic certification under the USDA National Organic Program (NOP) for its Portland SQF ... have established organic production and handling systems to complement our current rigorous food-safety ...
(Date:1/23/2017)... ... 23, 2017 , ... Old School Labs™, makers of the wildly popular all-natural ... Breon Ansley to its growing team of brand ambassadors. The Olympia top finisher and ... less than a year was able to turn professional, participating in the 2013 NPC ...
(Date:1/23/2017)... ... January 23, 2017 , ... Gynecology Associates of Gwinnett (GAoG) ... services for women of all ages. The staff of Gynecology Associates of ... services from routine health screenings to diagnosing and treating female concerns including menopause, ...
(Date:1/23/2017)... ... January 23, 2017 , ... “Crossing the Bar”: a moving and eloquent ... life. “Crossing the Bar” is the creation of published author, Charlotte Hotte, a North ... who credits the inspiration of the book to her sister, Denise, wishes to acknowledge ...
Breaking Medicine News(10 mins):